Ongoing Study:

Phase 1b/2 Study in AML in Poland

Multi-Center, Open-Label, Dose Escalation Study of Liposomal Annamycin for the Treatment of Subjects with Acute Myeloid Leukemia (AML)

Announced Prelim 60% ORR in Last Cohort of Single Agent AML Trial

Study Highlights:

Enrolling: ~75 Subjects

Treatment period: Infusions days 1, 2 & 3 with 21 days off

Does Escalation: Prelim RP2D of 240 mg/m2 established

Primary Endpoint: Establish safety and RP2D accomplished

Planned Phase 1/2 of Annamycin with Cytarabine (AnnAraC)
with 190 mg/m2 Initial Annamycin Dose

Based on sponsored research conducted in a highly aggressive AML mouse model, Annamycin in combination with Cytarabine (Cytarabine is also known as Ara-C, hence the combination is referred to as AnnAraC) demonstrated a 68% improvement in the median overall survival (OS) compared to Annamycin as a single agent and a 241% increase in OS compared to Cytarabine alone. Based on these data, the Company plans to advance its AML clinical development program in a Phase 1/2 clinical trial in Europe evaluating AnnArac utilizing the clinical data from its two prior Phase 1 clinical trials to establish the starting dose of 190 mg/m2.

For complete study details, please view the study listing on clinicaltrials.gov: ClinicalTrials.gov Identifier: NCT03388749

Our Pipeline

Publications

Sign Up For Alerts